Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1/2, Single Arm, Multicenter Clinical Trial to Investigate ALLO-501 in Patients with Relapsed/Refractory Large B-Cell lymphoma (Non-Hodgkin Lymphoma)

Trial Profile

An Open-Label, Phase 1/2, Single Arm, Multicenter Clinical Trial to Investigate ALLO-501 in Patients with Relapsed/Refractory Large B-Cell lymphoma (Non-Hodgkin Lymphoma)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs Allo 501 (Primary) ; ALLO 647 (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ALPHA
  • Sponsors Allogene Therapeutics
  • Most Recent Events

    • 28 Jan 2019 According to an Allogene Therapeutics media release, the U.S. Food & Drug Administration (FDA) has cleared Investigational New Drug (IND) application.
    • 03 Dec 2018 According to an Allogene Therapeutics media release, Allogene has exclusive rights from Servier to ALLO-501 in the United States, while Servier retains exclusive rights for all other countries.
    • 03 Dec 2018 According to an Allogene Therapeutics media release, the company plans to introduce its proprietary anti-CD52 mAb (ALLO-647) as part of the required lymphodepletion regimen.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top